Effect of exercise on older adults who have decreased muscle strength, muscle mass, and quality of life.

Effect of Reablement Strategies targeting Sarcopenia (ReStart-S) on muscle parameters, functional activities, and quality of life among older adults residing in long term care settings-A Cluster randomized trial - ReStart-S

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/10/046680

Enrollment

Registered

2022-10-20

Start date

Unknown

Completion date

Unknown

Last updated

2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M628- Other specified disorders of muscle

Interventions

Intervention1: Reablement Strategies targeting Sarcopenia (ReStart-S) program: Participants whose cluster (long term care setting) falls in the intervention group will undergo the ReStart-S program. T

Eligibility

Inclusion criteria

Inclusion criteria: (1) either gender, (2) more than or equal to 60 years of age to less than or equal to 99 years, (3) Barthel index more than or equal to 60 points, (4) Mini cog score more than or equal to 2 and normal clock drawing, (5) Sarcopenia as per the Asian Working Group for Sarcopenia 2019 (AWGS 2019) guidelines cut-off that is: (a) Appendicular skeletal muscle mass: <7.0 kilogram per meter square in men and <5.7 kilogram per meter square in women, (b) Hand Grip Strength: <28.0 kilogram for men and <18.0 kilogram for women, (c) Short Physical Performance Battery: less than or equal to 9

Exclusion criteria

Exclusion criteria: (1) Critically ill/ Terminally ill/ Active infection, (2) Pacemaker and any metal implant, (3) Bed bound/wheelchair bound, (4) Acute onset (less than 30 days) of cardiorespiratory/neurological/renal/orthopaedic disease

Design outcomes

Primary

Measure	Time frame
Hand Grip Strength (HGS, Kilogram)Timepoint: 0 week (baseline assessment), 6 weeks (minimum intervention duration), 12 weeks (minimum follow up duration post intervention)	—

Secondary

Measure	Time frame
(1) Physical performance: Short Physical Performance Battery (SPPB), (2) Muscle mass: Appendicular skeletal muscle mass (ASM, Kilogram/meter square), (3) Biomarker: C-terminal Agrin Fragment (CAF, nanograms per milliliter), (4) Activities of daily living: Katz Index of Independence in Activities of Daily Living, (5) Quality of life- Sarcopenia and Quality of Life questionnaire (SarQoL)Timepoint: 0 week (baseline assessment), 6 weeks (minimum intervention duration), 12 weeks (minimum follow up duration post intervention)	—

Measure

Time frame

(1) Physical performance: Short Physical Performance Battery (SPPB), (2) Muscle mass: Appendicular skeletal muscle mass (ASM, Kilogram/meter square), (3) Biomarker: C-terminal Agrin Fragment (CAF, nanograms per milliliter), (4) Activities of daily living: Katz Index of Independence in Activities of Daily Living, (5) Quality of life- Sarcopenia and Quality of Life questionnaire (SarQoL)Timepoint: 0 week (baseline assessment), 6 weeks (minimum intervention duration), 12 weeks (minimum follow up duration post intervention)

—

Countries

India

Contacts

Public ContactDr Shashikiran Umakanth

Manipal College of Health Professions

girish.n@manipal.edu9886782114

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026